News

Cyclo Therapeutics Provides Business Update

- Company on track to commence enrollment and dosing of Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer's disease before year end - Ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol® Cyclo™ for...

Cyclo Therapeutics to Present at the China NPC Association Meeting

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...

Trappsol® Cyclo™ is not currently approved for any indication.

Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.